Paper Details

  1. Home
  2. Paper Details

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.

Author: Atoria-SwartzCoral, De KoningHarry, HeijnsdijkEveline A M, LiljaHans, RoobolMonique J, ScardinoPeter T, SjobergDaniel D, ThompsonIan, UlmertDavid, VertosickEmily, VickersAndrew J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study using the US Surveillance, Epidemiology and End Results database and two clinical trial cohorts found that prostate cancer overdiagnosis has a strong relationship to age and PSA level. Restricting screening in men over 60 to those with PSA above median (>1 ng/ml) and screening men over 70 only in selected circumstances would importantly reduce overdiagnosis and change the ratio of benefits to harms of PSA-screening.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Prostate cancer screening depends on a careful balance of benefits, in terms of reduced prostate cancer mortality, and harms, in terms of overdiagnosis and overtreatment. We aimed to estimate the effect on overdiagnosis of restricting prostate specific antigen (PSA) testing by age and ba...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922189/

データ提供：米国国立医学図書館（NLM）

Understanding Prostate Cancer Overdiagnosis: Age and PSA Levels

Prostate cancer screening, using prostate-specific antigen (PSA) tests, is a complex issue with potential benefits and harms. While screening can identify early-stage cancer, it also can lead to overdiagnosis and overtreatment, which may not be beneficial to patients. This study examines the impact of age and PSA levels on prostate cancer overdiagnosis, highlighting the importance of careful screening practices.

Age and PSA: Key Factors in Overdiagnosis

The study found a strong relationship between age and PSA levels and prostate cancer overdiagnosis. Restricting PSA testing to older men with higher PSA levels could significantly reduce overdiagnosis. The researchers suggest that limiting screening to men over 60 with PSA levels above the median and screening men over 70 only in selected circumstances would substantially reduce overdiagnosis. This approach would help to balance the benefits and harms of PSA screening.

Navigating the Complexities of Prostate Cancer Screening

This research underscores the importance of personalized medicine in prostate cancer screening. It's not a one-size-fits-all approach. The study emphasizes the need for careful consideration of individual factors, such as age and PSA levels, when making screening decisions. This approach helps to ensure that men receive the most appropriate and beneficial care. Just as a camel navigates the desert based on its own unique abilities and the characteristics of the terrain, medical professionals should tailor their screening practices to each patient's specific circumstances.

Dr.Camel's Conclusion

This study highlights the importance of carefully considering age and PSA levels when deciding who to screen for prostate cancer. The findings suggest that a more targeted screening approach could significantly reduce overdiagnosis, leading to more effective and less invasive treatments. This research contributes to the ongoing dialogue about the optimal strategies for prostate cancer screening and underscores the importance of individualizing care for each patient.

Date :
  1. Date Completed 2014-08-25
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

24512643

DOI: Digital Object Identifier

PMC3922189

Related Literature

Article Analysis
・Effective treatment of prostate cancer screening
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.